Latest LipiGesic M Stories

SCHOFIELD, Wis., Nov. 13, 2012 /PRNewswire/ -- PuraMed BioScience(®), Inc,. (OTCQB: PMBS) announces that its homeopathic migraine formulation, LipiGesic(® )M, has been recognized as an excellent first-line therapy in the treatment of acute migraine. The declaration was made in the online article "Advances in Drug Development for Acute Migraine," [page 14] scheduled for publication in an upcoming printed issue of Drugs, a medical journal evaluating drugs and drug therapies read by...

SCHOFIELD, Wis., Dec. 21, 2011 /PRNewswire/ -- PuraMed BioScience, Inc. (OTCBB: PMBS) announced today, an outline of its plans for the national product launch of its clinically tested migraine treatment LipiGesic(R) M. The Company has always emphasized science as the key to their success and this year three of the top headache researchers in the United States conducted a Double-blind, Placebo controlled, clinical trial of LipiGesic(R) M. The study was peer reviewed and published in...